Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy

Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy

The use of sodium-glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes is steadily increasing. SGLT2 inhibitors are associated with weight loss, lowering of blood pressure, and low hypoglycemia risk along with beneficial cardiovascular and renoprotective effects. In view o...

Full description

Bibliographic Details
Main Authors: Eleni Papadokostaki, Evangelos Liberopoulos
Format: Article
Language:English
Published: Hindawi Limited 2019-01-01
Series:Case Reports in Endocrinology
Online Access:http://dx.doi.org/10.1155/2019/3901741
id doaj-b32f154d4f074e39bcefde815b082a29
record_format Article
spelling doaj-b32f154d4f074e39bcefde815b082a292020-11-25T01:33:54ZengHindawi LimitedCase Reports in Endocrinology2090-65012090-651X2019-01-01201910.1155/2019/39017413901741Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon MalignancyEleni Papadokostaki0Evangelos Liberopoulos1Emergency Department, General Hospital of Heraklion “Venizeleio-Pananeio,” Heraklion, 71409, GreeceDepartment of Internal Medicine, Faculty of Medicine, University of Ioannina, Ioannina, 45110, GreeceThe use of sodium-glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes is steadily increasing. SGLT2 inhibitors are associated with weight loss, lowering of blood pressure, and low hypoglycemia risk along with beneficial cardiovascular and renoprotective effects. In view of the increasing use of SGLT2i, physicians must be aware of their adverse effects. Euglycemic diabetic ketoacidosis (euDKA) is a well-recognized adverse effect of SGLT2i. We present here a case of euglycemic diabetic ketoacidosis secondary to dapagliflozin use in a type 2 diabetic patient with colon cancer. To the best of our knowledge, this is first report of SGLT2 inhibitor-associated euDKA in a patient with underlying colon cancer.http://dx.doi.org/10.1155/2019/3901741
collection DOAJ
language English
format Article
sources DOAJ
author Eleni Papadokostaki
Evangelos Liberopoulos
spellingShingle Eleni Papadokostaki
Evangelos Liberopoulos
Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy
Case Reports in Endocrinology
author_facet Eleni Papadokostaki
Evangelos Liberopoulos
author_sort Eleni Papadokostaki
title Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy
title_short Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy
title_full Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy
title_fullStr Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy
title_full_unstemmed Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy
title_sort euglycemic diabetic ketoacidosis secondary to dapagliflozin in a patient with colon malignancy
publisher Hindawi Limited
series Case Reports in Endocrinology
issn 2090-6501
2090-651X
publishDate 2019-01-01
description The use of sodium-glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes is steadily increasing. SGLT2 inhibitors are associated with weight loss, lowering of blood pressure, and low hypoglycemia risk along with beneficial cardiovascular and renoprotective effects. In view of the increasing use of SGLT2i, physicians must be aware of their adverse effects. Euglycemic diabetic ketoacidosis (euDKA) is a well-recognized adverse effect of SGLT2i. We present here a case of euglycemic diabetic ketoacidosis secondary to dapagliflozin use in a type 2 diabetic patient with colon cancer. To the best of our knowledge, this is first report of SGLT2 inhibitor-associated euDKA in a patient with underlying colon cancer.
url http://dx.doi.org/10.1155/2019/3901741
work_keys_str_mv AT elenipapadokostaki euglycemicdiabeticketoacidosissecondarytodapagliflozininapatientwithcolonmalignancy
AT evangelosliberopoulos euglycemicdiabeticketoacidosissecondarytodapagliflozininapatientwithcolonmalignancy
_version_ 1725075027787776000

Similar Items